<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6425EB61-C766-4D41-9717-074832FBE20A"><gtr:id>6425EB61-C766-4D41-9717-074832FBE20A</gtr:id><gtr:name>Peking University</gtr:name><gtr:address><gtr:line1>Peking University</gtr:line1><gtr:line2>5 Yiheyuan Rd</gtr:line2><gtr:line3>Haidian District</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>China</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6425EB61-C766-4D41-9717-074832FBE20A"><gtr:id>6425EB61-C766-4D41-9717-074832FBE20A</gtr:id><gtr:name>Peking University</gtr:name><gtr:address><gtr:line1>Peking University</gtr:line1><gtr:line2>5 Yiheyuan Rd</gtr:line2><gtr:line3>Haidian District</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>China</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C0D0D555-E243-40F7-ACE0-CD97A4D1DB93"><gtr:id>C0D0D555-E243-40F7-ACE0-CD97A4D1DB93</gtr:id><gtr:firstName>Lyn</gtr:firstName><gtr:surname>Chitty</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/534E81AC-9DCD-4969-9740-980D137F6062"><gtr:id>534E81AC-9DCD-4969-9740-980D137F6062</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Copp</gtr:surname><gtr:orcidId>0000-0002-2544-9117</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DCC93C92-EDE7-463D-80C8-4BA984E55BAA"><gtr:id>DCC93C92-EDE7-463D-80C8-4BA984E55BAA</gtr:id><gtr:firstName>Therese</gtr:firstName><gtr:surname>Hesketh</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BAA12657-4EC0-44F2-8692-7F31391D0C43"><gtr:id>BAA12657-4EC0-44F2-8692-7F31391D0C43</gtr:id><gtr:firstName>Nicholas</gtr:firstName><gtr:surname>Greene</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0401315"><gtr:id>6E4C51E6-1118-4139-B678-7A05EABF23FB</gtr:id><gtr:title>Neurodegeneration before birth: can inositol increase prevention of neural tube defects in conjunction with folic acid?</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0401315</gtr:grantReference><gtr:abstractText>Neural tube defects (NTDs) are serious birth defects that affect up to 1 in every 500 pregnancies in all countries. Around 120,000 pregnancies are affected in the world each year. The best known NTD malformation is spina bifida, in which children are often paralysed from the waist down. They need frequent operations to treat the many associated medical conditions, including incontinence of urine and faeces and deformities of the vertebral column. Over the past 15 years, it has emerged that folic acid, a B-group vitamin, if taken in the first few weeks of pregnancy, can prevent the onset of spina bifida and other NTDs, ensuring the birth of a normal baby. However, it is clear that not all cases of NTD are preventable by folic acid. NTDs come in different ?types?, with only certain types being responsive to folic acid. Work in the mouse has shown that another vitamin-like molecule, inositol, can prevent NTDs where folic acid is ineffective. Evidence has now accumulated, in mice and humans, to suggest that inositol would be a safe and possibly effective ?extra? therapy to use in conjunction with folic acid, to protect against more types of NTD than with either agent alone. Here, we propose to carry out a pilot study in which we will randomly assign women, contemplating a pregnancy, to supplementation with folic acid alone (the control group) or folic acid plus inositol (the study group). Women who have had a previous NTD pregnancy will be invited to enter the trial, as they are at high risk of a further NTD pregnancy. The treatment group will not be known either to the mother or to the physician treating her, until the pilot study is completed and the data are analysed. Statistical analysis will be used to compare the frequency of further NTD pregnancies in the study and control groups, to determine whether addition of inositol to the standard folic acid therapy lowers the frequency of NTDs. If a positive result emerges, this study could pave the way for a new, improved method of preventing NTDs in human pregnancy. The findings of the study will be published, presented at conferences, disseminated via the Institute of Child Health/Great Ormond Street website and communicated to patient groups (e.g. the Association for Spina Bifida and Hydrocephalus). Future intensive public campaigns will be necessary if inositol proves effective in this clinical trial.</gtr:abstractText><gtr:technicalSummary>Neural tube defects (NTDs) are severe malformations of the CNS, occurring in 0.5 to 2 per 1000 pregnancies, and resulting when the embryonic neural tube fails to close. Exposure to the amniotic fluid environment leads to neurodegeneration during pregnancy and, by birth, the exposed brain and/or spinal cord are totally degenerate. Fetuses with brain NTDs (e.g. anencephaly) are stillborn and those with spinal NTDs (e.g. myelomeningocele) are neurologically impaired below the lesion.

Folic acid (FA), administered early in pregnancy, can prevent up to 70% of NTDs (Lancet, 1991, 338, 131-7). However, a proportion of NTDs do not respond to FA and currently cannot be prevented. Some mouse models of NTD show prevention by FA whereas others are resistant. We found that inositol (both myo- and D-chiro- forms), prevents NTDs in a FA-resistant mouse model. Moreover, serum inositol is lower in mothers and children with NTDs. Pre-clinical animal testing, and limited testing in humans, suggest that inositol therapy is safe in pregnancy.

We propose to develop a randomised, double blind clinical trial protocol to compare (i) FA alone with (ii) FA plus D-chiro-inositol, for prevention of NTD recurrence. In this project, we will: (a) establish a network of collaborators in UK and Europe who can recruit trial subjects with a previous NTD pregnancy; (b) develop laboratory assays for inositol to monitor compliance and investigate levels in trial subjects; (c) conduct a pilot trial in the UK to determine feasibility and enable accurate power analysis for a larger scale trial.</gtr:technicalSummary><gtr:fund><gtr:end>2008-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>121875</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Peking University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>Peking University NTD collaboration</gtr:description><gtr:id>A75A23A9-C00E-4DF6-A547-599245618974</gtr:id><gtr:impact>None to date</gtr:impact><gtr:outcomeId>58beb1a18c6253.56222416-1</gtr:outcomeId><gtr:partnerContribution>Collaborators at PKU are providing access to women at high risk of neural tube defects in China, to allow a large-scale clinical trial to follow up from the PONTI pilot study in the UK.</gtr:partnerContribution><gtr:piContribution>Our work with inositol supplementation in mice, and our PONTI pilot clinical trial in the UK, posed the hypothesis that inositol can increase the prevention of neural tube defects, alongside folic acid.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Links to patient group web sites</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>37476941-25B9-4E3D-B736-8BBA4AC358DC</gtr:id><gtr:impact>Articles were written and posted on the web sites of the Association for Spina Bifida and Hydrocephalus, and other charities. Following publication of the PONTI pilot study in Feb 2016, various articles appeared including one on the SHINE web site - see URL below.

Improved visibility of the clinical trial and increased interest from potential trial subjects</gtr:impact><gtr:outcomeId>3F44C9DA456</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.shinecharity.org.uk/mediaccentre/news/2016/02/10/new-research-findings-bring-prevention-hope-for-spina-bifida</gtr:url><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PONTI trial web site</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CCE977CD-FC8C-4E0B-891A-62BB346776A5</gtr:id><gtr:impact>The clinical trial is named PONTI: Prevention of Neural Tube Defects by Inositol. The original web site (2006-12) provided information for prospective trial subjects, encouraging them to enroll in the clinical trial. Since the trial has finished, this web page is no longer displayed.

In 2016, following the publication of the PONTI study in the British Journal of Nutrition, we have dedicated a page of the NTD Group web site (UCL Institute of Child Health) to the PONTI study - see URL below.

Significant interest in the clinical trial has arisen in part from the web site, and has led to continuing recruitment of patients into the trial</gtr:impact><gtr:outcomeId>E58D4D94983</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.ucl.ac.uk/ich/research/developmental-biology-cancer/developmental-biology-birth-defects/copp-greene-research-group/ponti_study</gtr:url><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PONTI trial media publicity</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CF87EA70-3160-475D-9A4A-7E83F3D28928</gtr:id><gtr:impact>Interview with BBC health correspondent led to a piece published on the BBC News Scotland website (http://www.bbc.co.uk/news/uk-scotland-11230642). This prompted several interviews on BBC Breakfast TV, Radio Ulster, Radio 5 Live. Following publication of the PONTI paper (Feb 2016), there was further media attention: BBC News Scotland website (http://www.bbc.co.uk/news/uk-scotland-35503529), and the London Evening Standard.


Increased recruitment into the clinical trial, from women who had encountered the publicity.</gtr:impact><gtr:outcomeId>YJ5CqN4Jaeq</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/news/uk-scotland-35503529</gtr:url><gtr:year>2010,2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>67111</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>SPARKS PONTI trial grant</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Sparks</gtr:fundingOrg><gtr:fundingRef>09ICH01</gtr:fundingRef><gtr:id>D1EE900B-B31A-4520-88F7-A0141E648EF1</gtr:id><gtr:outcomeId>YVtLecgSTNQ0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>34353</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CLRN PONTI trial support costs</gtr:description><gtr:end>2012-01-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>F170FBDE-7BBD-47A1-AF1C-085BF0A5483B</gtr:id><gtr:outcomeId>H8sqwduGUFo0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Inositol supplementation advice</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>491754E9-701D-47DF-A25C-44082E461EA5</gtr:id><gtr:impact>Occurrence of neural tube defects (spina bifida, anencephaly) in families where women have taken folic acid at the recommended level, leaves these families confused and worried about the future, and their ability to have a normal child. They expect that folic acid will protect them in pregnancy, and are shocked when it sometimes does not. Our introduction of inositol as a possible adjunct preventive supplement has become widely known in the UK and beyond. We regularly receive requests for information and guidance, both from families and from medical doctors who are looking after families with previously affected pregnancies. Hence, inositol supplementation is already making a significant difference to the planning of pregnancies in women at high risk of spina bifida.</gtr:impact><gtr:outcomeId>54edbe280649a9.99363481</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A proportion of neural tube defects (NTDs; e.g. spina bifida) are resistant to folic acid supplementation, whereas animal model research, in our laboratory, has indicated a preventive action of inositol in cases where folic acid is ineffective. The PONTI pilot randomized clinical trial has been completed having been started with funding from this MRC Trial Platform Grant. It sought to determine whether inositol treatment, in conjunction with folic acid, may lead to a reduction in the frequency of neural tube defects compared with use of folic acid alone. While the study was small, and not fully powered to detect a statistical effect of inositol, nevertheless we found 3 recurrences of NTD in patients taking folic acid alone, but zero recurrences in a larger group of patients who took inositol plus folic acid. This is encouraging for a further, more statistically powered clinical trial in the coming years. The paper on the pilot study was published in the British Journal of Nutrition, Feb 2016.</gtr:description><gtr:id>E95F8E99-FDF3-44A4-A1C4-BF7E5F882278</gtr:id><gtr:impact>Knowledge of the suspected beneficial effects of inositol in pregnancies at high risk of neural tube defect is now widespread, following our animal model studies. A number of high risk pregnancies have been supplemented with inositol, so far with no recurrences. Hence, beneficial effects of inositol usage may be occurring already. Formal clinical trial evidence of inositol efficacy will be required from a future larger-scale study.</gtr:impact><gtr:outcomeId>FF8EBA50ECD</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>PONTI - Inositol for prevention of folic acid-resistant neural tube defects</gtr:title><gtr:type>Preventative Intervention - Nutrition and Chemoprevention</gtr:type><gtr:url>https://clinicaltrials.gov/ct2/show/NCT00452829?term=inositol&amp;rank=28</gtr:url><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>An HPLC-MS/MS method was developed allowing separation and selective detection of myo-inositol from other inositol stereoisomers. Inositol was also separated from contaminating hexose monosaccharides of the same molecular weight, including glucose, galactose, mannose and fructose. This method can be used on both blood and urine samples to accurately estimate inositol concentration</gtr:description><gtr:id>95EAA704-01F2-4272-A87B-CD467D237A1D</gtr:id><gtr:impact>Method has been published and so available to all interested parties. Technique is in active use in our ongoing clinical trial of inositol supplementation in human pregnancy to prevent neural tube defects</gtr:impact><gtr:outcomeId>PdxZsv8mK2m</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Inositol assay</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/pubmed/21856255?dopt=Citation</gtr:url></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>44437664-76E8-4C06-8BE3-12F18C04F4F6</gtr:id><gtr:title>Abnormal folate metabolism in foetuses affected by neural tube defects.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a09407addd4a9138a3a0d5b16176858"><gtr:id>9a09407addd4a9138a3a0d5b16176858</gtr:id><gtr:otherNames>Dunlevy LP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>B0017F875DE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFDEB29A-EB16-430D-9713-6F953C4C3DB4</gtr:id><gtr:title>The genetic background of the curly tail strain confers susceptibility to folate-deficiency-induced exencephaly.</gtr:title><gtr:parentPublicationTitle>Birth defects research. Part A, Clinical and molecular teratology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3786b3eb827e7974c346cd8ec94580b"><gtr:id>d3786b3eb827e7974c346cd8ec94580b</gtr:id><gtr:otherNames>Burren KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1542-0752</gtr:issn><gtr:outcomeId>pm_12437_17_19824061</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C07931C-8B4E-4250-ABF1-9C4CD21AE397</gtr:id><gtr:title>Quantitative analysis of myo-inositol in urine, blood and nutritional supplements by high-performance liquid chromatography tandem mass spectrometry.</gtr:title><gtr:parentPublicationTitle>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84b0afb3708c72086570db9854438ed7"><gtr:id>84b0afb3708c72086570db9854438ed7</gtr:id><gtr:otherNames>Leung KY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1570-0232</gtr:issn><gtr:outcomeId>nsuLELJ7Hx9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A72A3F2-C085-48B3-AB03-9E7D4A862588</gtr:id><gtr:title>Nucleotide precursors prevent folic acid-resistant neural tube defects in the mouse.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84b0afb3708c72086570db9854438ed7"><gtr:id>84b0afb3708c72086570db9854438ed7</gtr:id><gtr:otherNames>Leung KY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_12437_27_23935126</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB9799A0-69A9-4A60-80B0-A80A14CFD94C</gtr:id><gtr:title>Mutations in genes encoding the glycine cleavage system predispose to neural tube defects in mice and humans.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/521fb48b632ee7f4cbceb41ead2ab124"><gtr:id>521fb48b632ee7f4cbceb41ead2ab124</gtr:id><gtr:otherNames>Narisawa A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>54ede82f7eb580.06586462</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B05F1C22-52A7-4301-B29A-F3E9CE82C608</gtr:id><gtr:title>Inositol, neural tube closure and the prevention of neural tube defects.</gtr:title><gtr:parentPublicationTitle>Birth defects research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/05d5ad6709a1d670da68174acc885ac4"><gtr:id>05d5ad6709a1d670da68174acc885ac4</gtr:id><gtr:otherNames>Greene ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1542-0752</gtr:issn><gtr:outcomeId>58bd9ff4667e27.42212330</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1598122F-831E-4032-AA9A-A2F6DB5D6FA1</gtr:id><gtr:title>Folate metabolite profiling of different cell types and embryos suggests variation in folate one-carbon metabolism, including developmental changes in human embryonic brain.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84b0afb3708c72086570db9854438ed7"><gtr:id>84b0afb3708c72086570db9854438ed7</gtr:id><gtr:otherNames>Leung KY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0300-8177</gtr:issn><gtr:outcomeId>5460add08f6fb9.39101433</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AF9C98F-56E1-4503-9E79-CC1CDA97011B</gtr:id><gtr:title>Gene-environment interactions in the causation of neural tube defects: folate deficiency increases susceptibility conferred by loss of Pax3 function.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3786b3eb827e7974c346cd8ec94580b"><gtr:id>d3786b3eb827e7974c346cd8ec94580b</gtr:id><gtr:otherNames>Burren KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>4396C89B5D9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0EEB4A5-1AE7-4881-84F9-1E86940BAD66</gtr:id><gtr:title>Neural tube defects induced by folate deficiency in mutant curly tail (Grhl3) embryos are associated with alteration in folate one-carbon metabolism but are unlikely to result from diminished methylation.</gtr:title><gtr:parentPublicationTitle>Birth defects research. Part A, Clinical and molecular teratology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d26ee11f574ee83f0b765efd4a21c283"><gtr:id>d26ee11f574ee83f0b765efd4a21c283</gtr:id><gtr:otherNames>De Castro SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1542-0752</gtr:issn><gtr:outcomeId>pm_12437_27_20589880</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE14CECF-9B40-49ED-AB72-4855C53CC9B9</gtr:id><gtr:title>Inositol for the prevention of neural tube defects: a pilot randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>The British journal of nutrition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/05d5ad6709a1d670da68174acc885ac4"><gtr:id>05d5ad6709a1d670da68174acc885ac4</gtr:id><gtr:otherNames>Greene ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-1145</gtr:issn><gtr:outcomeId>56cdbb871dc446.46957345</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>630C8DBE-20E1-4C25-9965-47884B666209</gtr:id><gtr:title>Genetics and development of neural tube defects.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08e4ace1bcd4ed13d992a5c3970c5371"><gtr:id>08e4ace1bcd4ed13d992a5c3970c5371</gtr:id><gtr:otherNames>Copp AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>5FE616EE138</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52609396-9F49-4E18-934F-09BFFFF50941</gtr:id><gtr:title>Partitioning of One-Carbon Units in Folate and Methionine Metabolism Is Essential for Neural Tube Closure.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84b0afb3708c72086570db9854438ed7"><gtr:id>84b0afb3708c72086570db9854438ed7</gtr:id><gtr:otherNames>Leung KY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a97e5e41755b9.15470608</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB952C24-0588-446A-90E9-E706D7457F9D</gtr:id><gtr:title>Knowledge and periconceptional use of folic acid for the prevention of neural tube defects in ethnic communities in the United Kingdom: systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>Birth defects research. Part A, Clinical and molecular teratology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a407e9a9a3c9c9486f77bc3b7520c895"><gtr:id>a407e9a9a3c9c9486f77bc3b7520c895</gtr:id><gtr:otherNames>Peake JN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1542-0752</gtr:issn><gtr:outcomeId>pm_12437_27_23873812</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58230F4F-A8B3-4AA1-B072-656F898796FE</gtr:id><gtr:title>Understanding the causes and prevention of neural tube defects: Insights from the splotch mouse model.</gtr:title><gtr:parentPublicationTitle>Birth defects research. Part A, Clinical and molecular teratology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/05d5ad6709a1d670da68174acc885ac4"><gtr:id>05d5ad6709a1d670da68174acc885ac4</gtr:id><gtr:otherNames>Greene ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1542-0752</gtr:issn><gtr:outcomeId>3DB9692545C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30BDFC3A-EDB6-4301-99B2-88FF495D8D0D</gtr:id><gtr:title>Evaluation of folate metabolism gene polymorphisms as risk factors for open and closed neural tube defects.</gtr:title><gtr:parentPublicationTitle>American journal of medical genetics. Part A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf361fa9904eec885ccda2db3e2f5341"><gtr:id>cf361fa9904eec885ccda2db3e2f5341</gtr:id><gtr:otherNames>Doudney K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1552-4825</gtr:issn><gtr:outcomeId>54ede830c81651.84441229</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C1FB45A-7C2C-44D7-9B36-FA892D44187C</gtr:id><gtr:title>Quantitative analysis of s-adenosylmethionine and s-adenosylhomocysteine in neurulation-stage mouse embryos by liquid chromatography tandem mass spectrometry.</gtr:title><gtr:parentPublicationTitle>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3786b3eb827e7974c346cd8ec94580b"><gtr:id>d3786b3eb827e7974c346cd8ec94580b</gtr:id><gtr:otherNames>Burren KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1570-0232</gtr:issn><gtr:outcomeId>32962956080</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0401315</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>FA7AA693-7EDD-4A7E-8CA3-6B5658FBF717</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Reproductive Health and Childbirth</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>4F7FE31F-D266-4FE9-9BAB-3D21E9B789BA</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.3  Nutrition and chemoprevention</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>